(19)
(11) EP 2 542 583 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.12.2017 Bulletin 2017/50

(45) Mention of the grant of the patent:
25.10.2017 Bulletin 2017/43

(21) Application number: 11700068.7

(22) Date of filing: 07.01.2011
(51) International Patent Classification (IPC): 
C07K 16/26(2006.01)
A61P 35/00(2006.01)
A61K 39/395(2006.01)
(86) International application number:
PCT/EP2011/000048
(87) International publication number:
WO 2011/083090 (14.07.2011 Gazette 2011/28)

(54)

METHODS FOR TREATING BREAST CANCER

VERFAHREN ZUR BEHANDLUNG VON BRUSTKREBS

MÉTHODES DE TRAITEMENT DU CANCER DU SEIN


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 08.01.2010 US 293612 P

(43) Date of publication of application:
09.01.2013 Bulletin 2013/02

(73) Proprietors:
  • Progastrine et Cancers S.à r.l.
    1450 Luxembourg (LU)
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    75654 Paris Cédex 13 (FR)
  • Centre National de la Recherche Scientifique (CNRS)
    75794 Paris Cedex 16 (FR)

(72) Inventors:
  • FLOCH, Jean-François
    34200 Sète (FR)
  • HOUHOU, Leïla
    34090 Montpellier (FR)
  • CAILLER, Françoise
    34000 Montpellier (FR)
  • JOUBERT, Dominique
    34200 Sète (FR)
  • HOLLANDE, Frédéric
    34790 Grabels (FR)

(74) Representative: Regimbeau 
La Coupole Sud 379, rue Léon Blum
34000 Montpellier
34000 Montpellier (FR)


(56) References cited: : 
EP-A1- 2 062 597
WO-A1-2006/032980
WO-A1-2009/042618
WO-A1-01/62288
WO-A1-2008/076454
US-A1- 2006 051 818
   
  • CHAPMAN ANDREW P: "PEGylated antibodies and antibody fragments for improved therapy: A review", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 54, no. 4, 17 June 2002 (2002-06-17), pages 531-545, XP002300924, ISSN: 0169-409X, DOI: DOI:10.1016/S0169-409X(02)00026-1
  • PETKOVA STEFKA B ET AL: "Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 18, no. 12, 1 December 2006 (2006-12-01), pages 1759-1769, XP002539987, ISSN: 0953-8178, DOI: DOI:10.1093/INTIMM/DXL110
  • JIANG C -P ET AL: "Expression of gastrin receptor in tumors and its application as a molecular target for cancer diagnosis and therapy", WORLD CHINESE JOURNAL OF DIGESTOLOGY 200704 CN, vol. 15, no. 9, April 2007 (2007-04), pages 980-985, XP9145446, ISSN: 1009-3079
  • REUBI J C ET AL: "CHOLECYSTOKININ(CCK)-A AND CCK-B/GASTRIN RECEPTORS IN HUMAN TUMORS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 57, no. 7, 1 April 1997 (1997-04-01), pages 1377-1386, XP001206058, ISSN: 0008-5472
  • PIYUSH B. GUPTA ET AL: "Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening", CELL, vol. 138, no. 4, 1 August 2009 (2009-08-01), pages 645-659, XP55001903, ISSN: 0092-8674, DOI: 10.1016/j.cell.2009.06.034
  • DUFFY: "Biochemical markers in breast cancer: which ones are clinically useful?", CLINICAL BIOCHEMISTRY, vol. 34, no. 5, 1 July 2001 (2001-07-01), pages 347-52, XP55001919, ISSN: 0009-9120
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).